Literature DB >> 23721238

Rounding behavior in the reporting of headache frequency complicates headache chronification research.

Timothy T Houle1, Dana P Turner, Thomas A Houle, Todd A Smitherman, Vincent Martin, Donald B Penzien, Richard B Lipton.   

Abstract

OBJECTIVES: To characterize the extent of measurement error arising from rounding in headache frequency reporting (days per month) in a population sample of headache sufferers.
BACKGROUND: When reporting numerical health information, individuals tend to round their estimates. The tendency to round to the nearest 5 days when reporting headache frequency can distort distributions and engender unreliability in frequency estimates in both clinical and research contexts.
METHODS: This secondary analysis of the 2005 American Migraine Prevalence and Prevention study survey characterized the population distribution of 30-day headache frequency among community headache sufferers and determined the extent of numerical rounding ("heaping") in self-reported data. Headache frequency distributions (days per month) were examined using a simplified version of Wang and Heitjan's approach to heaping to estimate the probability that headache sufferers round to a multiple of 5 when providing frequency reports. Multiple imputation was used to estimate a theoretical "true" headache frequency.
RESULTS: Of the 24,000 surveys, headache frequency data were available for 15,976 respondents diagnosed with migraine (68.6%), probable migraine (8.3%), or episodic tension-type headache (10.0%); the remainder had other headache types. The mean number of headaches days/month was 3.7 (standard deviation = 5.6). Examination of the distribution of headache frequency reports revealed a disproportionate number of responses centered on multiples of 5 days. The odds that headache frequency was rounded to 5 increased by 24% with each 1-day increase in headache frequency (odds ratio: 1.24, 95% confidence interval: 1.23 to 1.25), indicating that heaping occurs most commonly at higher headache frequencies. Women were more likely to round than men, and rounding decreased with increasing age and increased with symptoms of depression.
CONCLUSIONS: Because of the coarsening induced by rounding, caution should be used when distinguishing between episodic and chronic headache sufferers using self-reported estimates of headache frequency. Unreliability in frequency estimates is of particular concern among individuals with high-frequency (chronic) headache. Employing shorter recall intervals when assessing headache frequency, preferably using daily diaries, may improve accuracy and allow more precise estimation of chronic migraine onset and remission.
© 2013 American Headache Society.

Entities:  

Mesh:

Year:  2013        PMID: 23721238      PMCID: PMC4546843          DOI: 10.1111/head.12126

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  18 in total

1.  Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers.

Authors:  W F Stewart; R B Lipton; K B Kolodner; J Sawyer; C Lee; J N Liberman
Journal:  Pain       Date:  2000-10       Impact factor: 6.961

2.  The International Classification of Headache Disorders: 2nd edition.

Authors: 
Journal:  Cephalalgia       Date:  2004       Impact factor: 6.292

3.  Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators.

Authors:  Peer Tfelt-Hansen; Julio Pascual; Nabih Ramadan; Carl Dahlöf; Domenico D'Amico; Hans-Christopher Diener; Jakob Møller Hansen; Michel Lanteri-Minet; Elisabeth Loder; Douglas McCrory; Sandra Plancade; Todd Schwedt
Journal:  Cephalalgia       Date:  2012-01       Impact factor: 6.292

4.  The PHQ-9: validity of a brief depression severity measure.

Authors:  K Kroenke; R L Spitzer; J B Williams
Journal:  J Gen Intern Med       Date:  2001-09       Impact factor: 5.128

Review 5.  Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability.

Authors:  W F Stewart; R B Lipton; A J Dowson; J Sawyer
Journal:  Neurology       Date:  2001       Impact factor: 9.910

6.  Migraine prevalence, disease burden, and the need for preventive therapy.

Authors:  R B Lipton; M E Bigal; M Diamond; F Freitag; M L Reed; W F Stewart
Journal:  Neurology       Date:  2007-01-30       Impact factor: 9.910

7.  Probable migraine in the United States: results of the American Migraine Prevalence and Prevention (AMPP) study.

Authors:  S Silberstein; E Loder; S Diamond; M L Reed; M E Bigal; R B Lipton
Journal:  Cephalalgia       Date:  2007-03       Impact factor: 6.292

8.  Prevalence and characteristics of allodynia in headache sufferers: a population study.

Authors:  M E Bigal; S Ashina; R Burstein; M L Reed; D Buse; D Serrano; R B Lipton
Journal:  Neurology       Date:  2008-04-22       Impact factor: 9.910

9.  Healthcare provider-patient communication and migraine assessment: results of the American Migraine Communication Study, phase II.

Authors:  Steven R Hahn; Richard B Lipton; Fred D Sheftell; Roger K Cady; Corey A Eagan; Suzanne E Simons; Meaghan R Nelson
Journal:  Curr Med Res Opin       Date:  2008-05-07       Impact factor: 2.580

10.  Migraine in adolescents: association with socioeconomic status and family history.

Authors:  M E Bigal; R B Lipton; P Winner; M L Reed; S Diamond; W F Stewart
Journal:  Neurology       Date:  2007-07-03       Impact factor: 9.910

View more
  8 in total

Review 1.  Rethinking headache chronification.

Authors:  Dana P Turner; Todd A Smitherman; Donald B Penzien; Richard B Lipton; Timothy T Houle
Journal:  Headache       Date:  2013-06       Impact factor: 5.887

2.  Cost-effectiveness analysis of non-invasive vagus nerve stimulation for the treatment of chronic cluster headache.

Authors:  James Morris; Andreas Straube; Hans-Christoph Diener; Fayyaz Ahmed; Nicholas Silver; Simon Walker; Eric Liebler; Charly Gaul
Journal:  J Headache Pain       Date:  2016-04-22       Impact factor: 7.277

3.  Migraine day frequency in migraine prevention: longitudinal modelling approaches.

Authors:  Gian Luca Di Tanna; Joshua K Porter; Richard B Lipton; Alan Brennan; Stephen Palmer; Anthony J Hatswell; Sandhya Sapra; Guillermo Villa
Journal:  BMC Med Res Methodol       Date:  2019-01-23       Impact factor: 4.615

4.  Neuroimaging features of whole-brain functional connectivity predict attack frequency of migraine.

Authors:  Junya Mu; Tao Chen; Shilan Quan; Chen Wang; Ling Zhao; Jixin Liu
Journal:  Hum Brain Mapp       Date:  2019-11-04       Impact factor: 5.038

5.  Prevalence and characteristics of cutaneous allodynia in probable migraine.

Authors:  Seung Min Han; Kyung Min Kim; Soo-Jin Cho; Kwang Ik Yang; Daeyoung Kim; Chang-Ho Yun; Min Kyung Chu
Journal:  Sci Rep       Date:  2021-01-28       Impact factor: 4.379

6.  Translation and validation of the Child and the Adolescent HARDSHIP (Headache-attributed restriction, disability, social handicap and impaired participation) questionnaire into Danish language.

Authors:  Jens Erik Jorgensen; Kate A McGirr; Hanne Oertved Korsgaard; Michael S Rathleff
Journal:  PeerJ       Date:  2016-04-14       Impact factor: 2.984

7.  Translation of the Child and Adolescent HARDSHIP (Headache-Attributed Restriction, Disability, Social Handicap and Impaired Participation) Questionnaire into the Lithuanian Language and Validation of Its HRQoL (Headache-Related Quality of Life) Scale.

Authors:  Diana Genc; Apolinaras Zaborskis; Nerija Vaičienė-Magistris
Journal:  Int J Environ Res Public Health       Date:  2018-07-25       Impact factor: 3.390

8.  Comparing prospective headache diary and retrospective four-week headache questionnaire over 20 weeks: Secondary data analysis from a randomized controlled trial.

Authors:  Vanessa E Miller; Keturah R Faurot; Olafur S Palssson; Beth A MacIntosh; Chirayath Suchindran; Gilson Honvoh; Susan Gaylord; Christopher E Ramsden; J Douglas Mann
Journal:  Cephalalgia       Date:  2020-08-16       Impact factor: 6.075

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.